Drug Trial Radar · NCT07073534
Phase I/II Clinical Study of SHR-1501 Combined With Adbelizumab in Patients With Malignant Tumors
Last checked: Nov 19, 2026Latest source record: Jan 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
203
Planned (sponsor's estimate)
Start
Jul 24, 2025
Primary completion
Dec 2027
Study completion Dec 2027
Sponsor
- Lead sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jul 18, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is an open, multicenter phase I/II clinical study. The entire study is divided into three stages: dose escalation, dose expansion, and efficacy expansion. Objective: To evaluate the objective response rate (ORR), safety and tolerability of the combination of SHR-1501 and adibelizumab in the treatment of advanced malignant tumors, and to provide the recommended dose (RP2D) for subsequent clinical studies.
Conditions
- Patients With Advanced or Metastatic Malignant Tumors
Interventions
SHR-1501, AdebrelimabDrug
the combination of SHR-1501 and Adebrelimab
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose-limiting toxicityTime frame: 21 Days or 28 days
- Maximum tolerated dose or Maximum-administered doseTime frame: Approximately 1 years
- Recommended Phase 2 dose (RP2D)Time frame: Approximately 2years.
- Objective response rate(ORR)Time frame: Approximately 2 years
- The incidence and severity of adverse events (AE)/serious adverse events (SAE) (rated based on CTCAE v5.0)Time frame: 21 Days,Approximately 2 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.